2019 10 clinical perspectives on ms disease progression ...heor • sick leave/pension •...
TRANSCRIPT
![Page 1: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/1.jpg)
Clinical perspectives on MS disease progression Jan Hillert
Karolinska Institutet and University Hospital
NP‐SE‐NA‐0038
10 2019
![Page 2: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/2.jpg)
Disclosures I
• Dr Hillert received a honorarium from Celgene AB to prepare and give this presentation
• Dr Hillert received honoraria for serving on advisory boards for Biogen and Sanofi-Genzyme and speaker’s fees from Biogen, Novartis, Merck, Bayer-Schering, Teva and Sanofi-Genzyme. He has served as P.I. for projects sponsored by, or received unrestricted research support from, Biogen, Merck, TEVA, Novartis and Sanofi-Genzyme. His MS research is funded by the Swedish Research Council and the Swedish Brain foundation.
![Page 3: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/3.jpg)
Disclosure II I want you to report to the Finnish MS registry!
![Page 4: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/4.jpg)
Progression of MS in the era ofdisease modifying treatments
Manouchehrinia et al, Multiple Sclerosis, 2017
• Slower progression than in all previous cohorts
![Page 5: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/5.jpg)
Born in 1980
Female
Onset in 2005
First EDSS 2.0
EDSS in 2006
46
7
27
52
43
169
Prediction of secondary progression: a nomogram
https://aliman.shinyapps.io/SPMSnom/
![Page 6: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/6.jpg)
SMSreg: A decision support tooland a scientific resource
![Page 7: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/7.jpg)
The SMSreg patient cohort
2019-12-10 Jan Hillert 7
N= EDSS Attacks DMT episodes
DMT now
Follow‐up yrs MRI CSF MSIS‐29 SDMT EQ5D
All 19,754 117,223 30,314 34,741 10,739 11,2 57,966 17,57 44,752 61,197 30,827
RRMS 11,564 71,247 20,423 24,698 8,985 8,7 45,041 9,771 36,745 50,49 26,166
SPMS 5,578 36,478 8,87 8,202 1,242 18,3 9,932 5,778 6,017 8,952 3,606
PPMS 1,695 6,638 316 948 236 11,4 1,652 1,431 629 607 507
8,870
![Page 8: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/8.jpg)
EDSS and MS courseIn a national registry
![Page 9: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/9.jpg)
Discovery Clinical Public data‐bases
2019-12-10 Jan Hillert 9
![Page 10: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/10.jpg)
2019-12-10 Jan Hillert 10
Swedish MS Registry• N=20,000 (18,000 active)• Demographics• Diagnostics• MRI (#lesions)• Attacks• EDSS• MSIS‐29• SDMT• EQ5D• Disease modifying treatment
Discovery Clinical Public data‐bases
N= 12,000/11,000 Questionnaire on exp.DNA/Genomics
• GWAS• Exome seq• GWSeq
Serum/Plasma• Proteomics• Viral serologies• NfL
RNAseqNAbs
Board of Health & research• Comorbidities• Health care consumption• Prescribed drugs• Pregnancy outcomesStatistics Sweden• Income/Earnings• EducationHealth Insurance Sweden• Sickness absence• Disability pensio n• Compensations
The Person Numbere.g.19551021‐0296
N= EDSS Attacks DMT episodes
DMT now
Follow‐up yrs MRI CSF MSIS‐29 SDMT EQ5D
All 19,754 117,223 30,314 34,741 10,739 11,2 57,966 17,57 44,752 61,197 30,827
RRMS 11,564 71,247 20,423 24,698 8,985 8,7 45,041 9,771 36,745 50,49 26,166
SPMS 5,578 36,478 8,87 8,202 1,242 18,3 9,932 5,778 6,017 8,952 3,606
PPMS 1,695 6,638 316 948 236 11,4 1,652 1,431 629 607 507
![Page 11: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/11.jpg)
The Swedish MS Registry:Research projects
HEOR• Sick leave/pension• Income/earnings/benefits• Cost of illness
Pharmacoepidemiology• Safety & Effectiveness:
– IMSE (since 2006)– COMBAT-MS (PCORI 8.3 MUSD)
• PASS (BMSD): Merck, Roche• Pragmatic trial: RIFUND• Long term effects of DMDs• Comparative effectiveness
Translational epidemiology• Multiple MS• NABINMS
Epidemiology• Genetic epidemiology• Prevalences/incidence• Trends• Environmental risks
Natural Course• Progression• Courses• Heterogeneity• Course by novel outcomes
Co‐morbidities• Autoimmunity• Psychiatry
”Real World Evidence”
![Page 12: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/12.jpg)
”The Poverty of Epidemiology” Perspectives in Biology and Medicine, Petr Skrabanek, 1992
”Higher prevalence of epidemiologists than ofproblems that epidemiology can solve”
”Any combination of exposure and disease, regardless of biologicalimplausibility, is fair game for calculating relative risks…”
![Page 13: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/13.jpg)
Epidemiology has improvedsince 1992
‐ Larger materials‐ Population‐base for representativtity‐ Statistical approaches to compensate for bias‐ All available/known confounders corrected for
![Page 14: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/14.jpg)
Disease progression in MS
• Ways to assess progression– Physical disability– Cognition– Socioeconomic outcomes
• What affects MS progression?– Life-style – e.g. smoking– Co-morbidities – e.g. depression– Disease modifying treatment
• Trends in MS progression
![Page 15: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/15.jpg)
Progression of MS in the era ofdisease modifying treatments
Manouchehrinia et al, Multiple Sclerosis, 2017
• Slower progression than in all previous cohorts: Change or completeness of coverage?
![Page 16: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/16.jpg)
p < 0.0001
0.00
0.25
0.50
0.75
1.00
0 20 40 60 80Time
Sur
viva
l pro
babi
lity
Strata Adult-onset Paediatric-onset
9420 9420 6591 1183 8468 425 79 0 0Paediatric-onsetAdult-onset
0 20 40 60 80Time
Stra
ta Number at risk
Survival curve of time from birth (a) and MS onset (b) to EDSS 4 in POMS versus AOMS.
a)
p < 0.0001
0.00
0.25
0.50
0.75
1.00
0 10 20 30 40Time
Sur
viva
l pro
babi
lity
Strata Adult-onset Paediatric-onset
9420 5162 1643 338 19468 295 123 42 5Paediatric-onsetAdult-onset
0 10 20 30 40Time
Stra
ta Number at risk
b)
![Page 17: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/17.jpg)
40
50
60
20 30 40 50
Age
SD
MT Adult-onset
Pediatric-onset
Mean SDMT score of POMS and AOMS by age at time of SDMT testing.
![Page 18: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/18.jpg)
Cost of illness increases with EDSS
![Page 19: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/19.jpg)
Disease progression in MS
• Ways to assess progression– Physical disability– Cognition– Socioeconomic outcomes
• What affects MS progression?– Life-style – e.g. smoking– Co-morbidities – e.g. depression– Disease modifying treatment
• Trends in MS progression
![Page 20: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/20.jpg)
Importance of smoking cessation
N= 332/118, retrospective design,
Quitters reach SPMS at age 55Continuers reach SPMS at age 48
Ramanujam et al. JAMA Neurol, 2015, 72:117-23
![Page 21: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/21.jpg)
Depression and bipolar disorderincrease the risk of MS progression
Stefanie Binzer; Kyla McKay; Philip Brenner; Jan Hillert; Ali Manouchehrinia,ECTRIMS 2018
The Swedish MS registry
The Swedish national patient registry
The Swedish national prescribed drug registry
![Page 22: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/22.jpg)
Depression and bipolar disorderincrease the risk of MS progression: EDSS 6
10th of October 2018 Stefanie Binzer 22
Patients with ICD code for depression showed a 2.1 times(95%CI:1.46‐2.77) increased risk
Patients exposed to SSRIs had a 2.2 times (95%CI:1.69‐2.94) increased risk
SB1
![Page 23: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/23.jpg)
Dia 22
SB1 Stefanie Binzer; 16.9.2018
![Page 24: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/24.jpg)
Early introduction of MS DMTsreduces the risk of progression: EDSS
<1 year: EDSS 4 at age 55>3 years: EDSS 4 at age 45
Risk of reaching EDSS 4, n= 639 , 8.25 years follow-up
Kavaliunas et al, 2017, Multiple Sclerosis Journal
![Page 25: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/25.jpg)
Impact of early treatment on long term disability accumulation in relapsing remitting multiple sclerosis patients
![Page 26: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/26.jpg)
Since 2014: The Big MS Data network
Participants:Italian MS Registry (M Trojano), Swedish MS Registry (J Hillert),
Danish MS Registry, (M Magyari ), OFSEP of France (S Vukusic), MSBase (H Butzkueven)
New opportunities on large pooled data sets
To lead and develop MS research on real world data Standards Methodology Community
Registry Established Number of centres
Estimated number of patients
Danish MS Registry 1948 22 25,000
Swedish MS Registry 2000 64 19,800
OFSEP (France) 1980 51,0000Italian MS Database Network
2001 26 48,500
MSBase 2001 210 58,000
![Page 27: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/27.jpg)
Early introduction of MS DMTsreduces the risk of progression: Pension
Journal of neurology 2018 265;3 701-707
![Page 28: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/28.jpg)
Importance of early initiation of 1st DMT: Loss of salary (to be published)
2019-12-10 Jan Hillert 27
![Page 29: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/29.jpg)
Disease progression in MS
• Ways to assess progression– Physical disability– Cognition– Socioeconomic outcomes
• What affects MS progression?– Life-style – e.g. smoking– Co-morbidities – e.g. depression– Disease modifying treatment
• Trends in MS progression
![Page 30: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/30.jpg)
Progression of MS in the era ofdisease modifying treatments
Manouchehrinia et al, Multiple Sclerosis, 2017
• Slower progression than in all previous cohorts: Change or completeness of coverage?
![Page 31: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/31.jpg)
CI, confidence interval; DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; HR, hazard ratio; POMS, progressive-onset MS; ROMS, relapsing-onset MSBeiki O et al. JAMA Neurol 2019;76:665–71
• 7331 patients from the Swedish MS registry, diagnosed between 1995 and 2010, were followed from the date of MS onset to the date of first sustained EDSS 3.0, 4.0 and 6.0
• After adjusting for confounding factors, a reduction in the risk of reaching EDSS milestones in patients with ROMS was found
– e.g. a patient diagnosed in 2010 has a 14% lower risk of reaching EDSS 3.0 than a patient diagnosed in 2005
– No significant effect was observed in patients with POMS
• This trend may be due to the increased use of DMDs over time, or to earlier diagnosis and treatment of MS
HR (95% CI) for reaching EDSS milestones per calendar year of diagnosis
EDSS 3.0
EDSS 4.0
EDSS 6.0
0,90 0,95 1,00 1,05
Reduced risk Increased riskROMS POMS
Figure developed using data from Beiki O et al. JAMA Neurol 2019;76:665–71
Hazard ratio
30
![Page 32: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/32.jpg)
MS cost of illness decreased from 2006–2012 due to lower indirect costs
SEK, Swedish kronaGyllensten H et al. Mult Scler 2018;24:520–8 31
Without MS
2006
MS patients Without MS MS patients Without MS MS patients
2009 2012
0
50,000
100,000
150,000
200,000
Aver
age
cost
s (S
EK
)
Figure from Gyllensten H et al. Comparing costs of illness of multiple sclerosis in three different years: a population-based study. Multiple Sclerosis 24(4), pp.
520–8. Copyright © 2018 by the Authors. Reprinted by permission of SAGE Publications, Ltd
€1 ≈ 10 SEK
Prescribed drugsOutpatient healthcare useInpatient healthcare useSick leaveDisability pension
![Page 33: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/33.jpg)
Disease progression in MS
• Ways to assess progression– Physical disability– Cognition– Socioeconomic outcomes
• What affects MS progression?– Life-style – e.g. smoking– Co-morbidities – e.g. depression– Disease modifying treatment
• Trends in MS progression
![Page 34: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/34.jpg)
Conclusions
• Several outcomes may be used to show MS progression– Disability– Cognitive performance– Quality of life– Socioeconomic outcomes
• MS long term outcomes may be influenced by– Life style– Co-mobidities– MS disease modifying treatments
• Times they are a’changing for persons with MS!
![Page 35: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/35.jpg)
Real world evidence in MS is an expanding research area
Big MS Data Network is a collaborative effort between five
MS registries which wasinitiated in 2014 with financial
support from Biogen
The participants are the national registries of Denmark, France, Italy and Sweden and
the international databasenetwork MSBase
![Page 36: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/36.jpg)
Remember:I want you to report to the Finnish MS registry!
![Page 37: 2019 10 Clinical perspectives on MS disease progression ...HEOR • Sick leave/pension • Income/earnings/benefits • Cost of illness Pharmacoepidemiology • Safety & Effectiveness:](https://reader034.vdocument.in/reader034/viewer/2022050602/5faa06a30c923d65410890a8/html5/thumbnails/37.jpg)
Thank you toHillert group• Anna Glaser• Ali Manouchehrinia• Ryan Ramanujam• Andrius Kavaliunas• Tim Spelman• Sahl Bedri• Omid Beiki• Virginia Karrenbauer• Katharina Fink
Swedish MS/Neuro regsitry• Leszek Stawiarz• Karin Lycke• Lillemor Bergström• Jenny Link
Karolinska MS network• Tomas Olsson• Lars Alfredsson• Kristina Alexanderson• Ingrid Kockum• Anna Fogdell-Hahn
Big MS Data• H. Butzkueven• Maria Trojano• Sandra Vukusic• Melinda Magyari
Helen TremlettStephen SawcerTomas Kalincik
Nordic MS Genetics groupIMSGC
Biogen - Rob HydeNovartisGenzyme
Thanks to all Swedish MS patients participating in the Swedish MS registry!